View ValuationCanatu Oyj 향후 성장Future 기준 점검 5/6Canatu Oyj (는) 각각 연간 59.7% 및 31.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 59.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.2% 로 예상됩니다.핵심 정보59.7%이익 성장률59.27%EPS 성장률Semiconductor 이익 성장30.0%매출 성장률31.5%향후 자기자본이익률9.17%애널리스트 커버리지Low마지막 업데이트14 Apr 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 21Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Tuomo Vahapassi is the most experienced director on the board, commencing their role in 2024. Independent Director Bernhard Stockmeyer was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Apr 17Canatu Oyj Elects Anette Engelhardt as Member of the BoardCanatu Plc at its Annual General Meeting held on April 16, 2026 announced the election of Anette Engelhardt as a new member of the Board of the Directors until the end of the next Annual General Meeting.공시 • Feb 11Canatu plc Appoints Antti Härmänmaa as Vice President, Legal and General Counsel, and Member of the Leadership Team, Effective 9 February 2026Canatu Plc has appointed Antti Härmänmaa as Vice President, Legal and General Counsel, and a member of the Leadership Team, effective 9 February 2026. The role is newly established and introduces Canatu's in-house legal function. In his role, Antti Härmänmaa is responsible for creating and leading Canatu's in-house legal function and providing legal counsel across the organization. His responsibilities cover legal, compliance, corporate governance, intellectual property rights, and contract matters. He will report to CEO Juha Kokkonen. Antti Härmänmaa (LL.M., Helsinki, New York University; eMBA, Aalto; b. 1979) brings extensive experience from senior legal leadership roles in international technology and media companies. He joins Canatu from Nokia Technologies, where he most recently served as Head of IP Legal and IP Business Services (2024-2026), following his role as Director, Legal & Compliance (2023-2024). Previously, Härmänmaa held senior legal leadership roles at Teosto (2017-2021) and at Sanoma (2008-2017). In addition, he serves as an Expert Member of the Market Court of Finland.공시 • Jan 07Canatu Plc Announces Composition Of Shareholders' Nomination BoardCanatu Plc announced the composition of its Shareholders’ Nomination Board. The members of Canatu Plc’s Shareholders’ Nomination Board have been appointed. The composition of the Shareholders’ Nomination Board is the following: Ari Ahola (appointed by eFruit International Inc.), Denis Cherkasov (appointed by Mymetics Holding (Cyprus) Limited), Shinichiro Nakamura (appointed by DENSO Corporation), Tuomo Vähäpassi (appointed by Inventure Fund Ky). The Nomination Board elected Ari Ahola as Chair from among its members. In accordance with the Charter of the Shareholders’ Nomination Board, the Shareholders’ Nomination Board consists of four members, representing Canatu’s four largest shareholders, who held the largest number of votes in Canatu based on the shareholders’ register as per the situation on the first banking day of October 2025, considering the nominee-registered shares, and exercised their right of appointment. As the fourth largest shareholder Varma Mutual Pension Insurance Company did not exercise its right of appointment, the right was transferred to the fifth largest shareholder in accordance with the Charter of the Shareholders’ Nomination Board, Inventure Fund Ky, which appointed the fourth member of the Shareholder’s Nomination Board. The Chair of Canatu’s Board of Directors participates in the Shareholders’ Nomination Board’s work as an expert without having a right to participate in the decision-making of the Shareholders’ Nomination Board. The Shareholders’ Nomination Board is a corporate body appointed by Canatu’s shareholders that is responsible for preparing proposals to the annual general meeting, and if necessary, to the extraordinary general meeting, on the number, election, and remuneration of the members of the Board of Directors.공시 • Aug 29+ 2 more updatesCanatu Oyj, Annual General Meeting, Apr 16, 2026Canatu Oyj, Annual General Meeting, Apr 16, 2026.공시 • Jul 11Canatu plc Receives Customer Approval for its CNT100 SEMI Receptor and Post-Processing Equipment, Enabling Mass Production of Advanced EUV PelliclesCanatu Plc has received Site Acceptance Test (SAT) approval for its first CNT100 SEMI reactor and for the related post-processing peripherals, shipped to a semiconductor customer in September 2024. The equipment successfully passed the extensive tests conducted on-site at the customer's premises and met the stringent technical requirements and specifications defined in the acceptance criteria. This confirms the CNT100 SEMI reactor's readiness for mass production of CNT pellicle membranes. The next step for the customer is to secure final approval for the ready CNT pellicle product and the complete manufacturing line, before pilot and risk mass production can begin. This phase would initiate the mass production of CNT peLLicle membranes, generating non-recurring revenue from technology licensing, as well as recurring revenue from royalties on CNT pellicle sales, and from reactor consumables. Site Acceptance Test (Sat) means that the equipment is tested on-site after Factory Acceptance Test (FAT) to ensure the reactor and peripherals operate as intended in real use conditions. The SAT process included several output and product quality tests. With the SAT approval, Canatu's CNT100 SEMI reactor & peripherals are now ready for mass production. Demand for advanced semiconductors is accelerating due to the rapid growth of artificial intelligence. EUV (Extreme Ultraviolet) lithography is gaining traction, especially for sub-7 nanometer chips--the fastest-growing segment. Canatu is well-positioned to support this shift with its advanced CNT pellicle membranes, which perform traditional composite pellicles. These membranes offer higher EUV transmission and greater thermal resistance, enabling them to withstand the extreme heat loads of 600W EUV lithography tools used to produce the most advanced chips.공시 • Jun 09+ 1 more updateCanatu plc Appoints Nedal Safwat as Chief Development Officer, and President of Canatu Inc, Effective June 9, 2025Canatu Plc announced the appointment of Dr. Nedal Safwat (PhD in Biochemistry) as Chief Development Officer, effective June 9, 2025. In his new role, Dr. Safwat will lead Canatu’s Medical Diagnostics business unit and serve as a member of the Management Team. Dr. Safwat brings over 20 years of industry expertise in medical diagnostics and a strong track record in business development across leading global organizations. Most recently, he served as Vice President, Portfolio and Program Management Office at Cepheid (2025). Before that, he served as the Vice President, Head of Molecular Diagnostics Sales and Marketing – North America at QIAGEN (2021–2024), and Vice President, Marketing and Business Development at ChromaCode Inc. (2020–2021). He also held multiple leadership roles in product development and commercial functions at bioMérieux (2009–2020).이익 및 매출 성장 예측DB:0CD - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028689914412/31/2027514-26412/31/202626-10-22-11412/31/202517-10-6-1N/A9/30/202514-9-7-3N/A6/30/202511-9-7-4N/A3/31/20257-6-8-6N/A12/31/20243-4-8-7N/A애널리스트 향후 성장 전망수입 대 저축률: 0CD 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(1.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: 0CD (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: 0CD 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: 0CD 의 수익(연간 31.5%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 0CD 의 수익(연간 31.5%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 0CD의 자본 수익률은 3년 후 9.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YSemiconductors 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 16:04종가2026/05/27 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Canatu Oyj는 5명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Waltteri RossiDanske BankMatti RiikonenDNB CarnegieMarianne PalmuInderes Oy2명의 분석가 더 보기
Board Change • May 21Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Tuomo Vahapassi is the most experienced director on the board, commencing their role in 2024. Independent Director Bernhard Stockmeyer was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Apr 17Canatu Oyj Elects Anette Engelhardt as Member of the BoardCanatu Plc at its Annual General Meeting held on April 16, 2026 announced the election of Anette Engelhardt as a new member of the Board of the Directors until the end of the next Annual General Meeting.
공시 • Feb 11Canatu plc Appoints Antti Härmänmaa as Vice President, Legal and General Counsel, and Member of the Leadership Team, Effective 9 February 2026Canatu Plc has appointed Antti Härmänmaa as Vice President, Legal and General Counsel, and a member of the Leadership Team, effective 9 February 2026. The role is newly established and introduces Canatu's in-house legal function. In his role, Antti Härmänmaa is responsible for creating and leading Canatu's in-house legal function and providing legal counsel across the organization. His responsibilities cover legal, compliance, corporate governance, intellectual property rights, and contract matters. He will report to CEO Juha Kokkonen. Antti Härmänmaa (LL.M., Helsinki, New York University; eMBA, Aalto; b. 1979) brings extensive experience from senior legal leadership roles in international technology and media companies. He joins Canatu from Nokia Technologies, where he most recently served as Head of IP Legal and IP Business Services (2024-2026), following his role as Director, Legal & Compliance (2023-2024). Previously, Härmänmaa held senior legal leadership roles at Teosto (2017-2021) and at Sanoma (2008-2017). In addition, he serves as an Expert Member of the Market Court of Finland.
공시 • Jan 07Canatu Plc Announces Composition Of Shareholders' Nomination BoardCanatu Plc announced the composition of its Shareholders’ Nomination Board. The members of Canatu Plc’s Shareholders’ Nomination Board have been appointed. The composition of the Shareholders’ Nomination Board is the following: Ari Ahola (appointed by eFruit International Inc.), Denis Cherkasov (appointed by Mymetics Holding (Cyprus) Limited), Shinichiro Nakamura (appointed by DENSO Corporation), Tuomo Vähäpassi (appointed by Inventure Fund Ky). The Nomination Board elected Ari Ahola as Chair from among its members. In accordance with the Charter of the Shareholders’ Nomination Board, the Shareholders’ Nomination Board consists of four members, representing Canatu’s four largest shareholders, who held the largest number of votes in Canatu based on the shareholders’ register as per the situation on the first banking day of October 2025, considering the nominee-registered shares, and exercised their right of appointment. As the fourth largest shareholder Varma Mutual Pension Insurance Company did not exercise its right of appointment, the right was transferred to the fifth largest shareholder in accordance with the Charter of the Shareholders’ Nomination Board, Inventure Fund Ky, which appointed the fourth member of the Shareholder’s Nomination Board. The Chair of Canatu’s Board of Directors participates in the Shareholders’ Nomination Board’s work as an expert without having a right to participate in the decision-making of the Shareholders’ Nomination Board. The Shareholders’ Nomination Board is a corporate body appointed by Canatu’s shareholders that is responsible for preparing proposals to the annual general meeting, and if necessary, to the extraordinary general meeting, on the number, election, and remuneration of the members of the Board of Directors.
공시 • Aug 29+ 2 more updatesCanatu Oyj, Annual General Meeting, Apr 16, 2026Canatu Oyj, Annual General Meeting, Apr 16, 2026.
공시 • Jul 11Canatu plc Receives Customer Approval for its CNT100 SEMI Receptor and Post-Processing Equipment, Enabling Mass Production of Advanced EUV PelliclesCanatu Plc has received Site Acceptance Test (SAT) approval for its first CNT100 SEMI reactor and for the related post-processing peripherals, shipped to a semiconductor customer in September 2024. The equipment successfully passed the extensive tests conducted on-site at the customer's premises and met the stringent technical requirements and specifications defined in the acceptance criteria. This confirms the CNT100 SEMI reactor's readiness for mass production of CNT pellicle membranes. The next step for the customer is to secure final approval for the ready CNT pellicle product and the complete manufacturing line, before pilot and risk mass production can begin. This phase would initiate the mass production of CNT peLLicle membranes, generating non-recurring revenue from technology licensing, as well as recurring revenue from royalties on CNT pellicle sales, and from reactor consumables. Site Acceptance Test (Sat) means that the equipment is tested on-site after Factory Acceptance Test (FAT) to ensure the reactor and peripherals operate as intended in real use conditions. The SAT process included several output and product quality tests. With the SAT approval, Canatu's CNT100 SEMI reactor & peripherals are now ready for mass production. Demand for advanced semiconductors is accelerating due to the rapid growth of artificial intelligence. EUV (Extreme Ultraviolet) lithography is gaining traction, especially for sub-7 nanometer chips--the fastest-growing segment. Canatu is well-positioned to support this shift with its advanced CNT pellicle membranes, which perform traditional composite pellicles. These membranes offer higher EUV transmission and greater thermal resistance, enabling them to withstand the extreme heat loads of 600W EUV lithography tools used to produce the most advanced chips.
공시 • Jun 09+ 1 more updateCanatu plc Appoints Nedal Safwat as Chief Development Officer, and President of Canatu Inc, Effective June 9, 2025Canatu Plc announced the appointment of Dr. Nedal Safwat (PhD in Biochemistry) as Chief Development Officer, effective June 9, 2025. In his new role, Dr. Safwat will lead Canatu’s Medical Diagnostics business unit and serve as a member of the Management Team. Dr. Safwat brings over 20 years of industry expertise in medical diagnostics and a strong track record in business development across leading global organizations. Most recently, he served as Vice President, Portfolio and Program Management Office at Cepheid (2025). Before that, he served as the Vice President, Head of Molecular Diagnostics Sales and Marketing – North America at QIAGEN (2021–2024), and Vice President, Marketing and Business Development at ChromaCode Inc. (2020–2021). He also held multiple leadership roles in product development and commercial functions at bioMérieux (2009–2020).